References
- FerlayJShinHRBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancer in 2008: GLOBOCAN 2008Int J Cancer2010127122893291721351269
- ScherHISawyersCLBiology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axisJ Clin Oncol200523328253826116278481
- LamontKRTindallDJMinireview: Alternative activation pathways for the androgen receptor in prostate cancerMol Endocrinol201125689790721436259
- ChenYSawyersCLScherHITargeting the androgen receptor pathway in prostate cancerCurr Opin Pharmacol20088444044818674639
- GuoZDaiBJiangTRegulation of androgen receptor activity by tyrosine phosphorylationCancer Cell200610430931917045208
- AsimMSiddiquiIAHafeezBBBaniahmadAMukhtarHSrc kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cellsOncogene200827253596360418223692
- Bristol-Myers Squibb CompanySPRYCEL®(Dasatinib) [Package Insert]Princeton, NJBristol-Myers Squibb Company2012 Available from: http://packageinserts.bms.com/pi/pi_sprycel.pdfAccessed February 5, 2013
- KoreckijTNguyenHBrownYuEYVessellaRLCoreyEDasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysisBr J Cancer2009101226326819603032
- NamSKimDChengJQAction of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cellsCancer Res200565209185918916230377
- ParkSIZhangJPhillipsKATargeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse modelCancer Res20086893323333318451159
- de VriesTJMullenderMGvan DuinMAThe Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclastsMol Cancer Res20097447648819372577
- AraujoJCMathewPArmstrongAJDasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a phase 1–2 studyCancer20121181637121976132
- NCCN [webpage on the Internet]Clinical Practice Guidelines in Oncology–Prostate Cancer V1.2012Fort WashingtonNational Comprehensive Cancer Network2012 Available from: http://www.nccn.orgAccessed March 27, 2012
- HorwichAParkerCBangmaCKatajaVESMO Guidelines Working GroupProstate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201021Suppl 5v129v13320555062
- SaadFHotteSJGuidelines for the management of castrate-resistant prostate cancerCan Urol Assoc J20104638038421191494
- AdamoVNotoLFranchinaTEmerging targeted therapies for castration-resistant prostate cancerFront Endocrinol (Lausanne)201237322666217
- NelsonJBFizaziKMillerKPhase 3, randomized, placebo- controlled study of zibotentan (ZD4054) in patients with castration- resistant prostate cancer metastatic to boneCancer2012118225709571822786751
- ScherHIJiaXChiKRandomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancerJ Clin Oncol201129162191219821483004
- Regeneron Pharmaceuticals IncSanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP®(Aflibercept) [Press Release]TarrytownRegeneron Pharmaceuticals, Inc2012 Available from: http://files.shareholder.com/downloads/REGN/0x0x557779/94df2942-a7b5-4ea1-9c17-5ba3bd98c198/REGN_News_2012_4_5_General_Releases.pdfAccessed December 6, 2012